Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2026-07-02 12:57:23 ET · period of report 2026-07-01 · accession 0001961994-26-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-02 12:57 | 2026-07-01 | EBS | Williams Paul Anthony | SVP, Products Business | S - Sale | $8.40 | -3,000 | 159.1K | -2% | -$25.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-01 | S | D | 3,000 | $8.40 | 159,098 | D | — | — | (F1) All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |